Treatment outcomes of prostate cancer patients with Gleason score 8–10 treated with definitive radiotherapy

Özyiğit, Gökhan; Onal, Cem; Igdem, Sefik; Alıcıkuş, Zümre Arıcan; İribaş, Ayça; Akın, Mustafa; Yalman, Deniz; Çetin, İlknur Alsan; Aksu, Melek Gamze; Atalar, Banu; Dinçbaş, Fazilet Öner; Hürmüz, Pervin; Güler, Ozan Cem; Aydın, Barbaros; Sert, Fatma; Yildirim, C.; Görken, İlknur Bilkay; Ağaoğlu, Fulya Yaman; Korcum, Aylin Fidan; Yüce, Deniz; Özkök, Serdar; Darendeliler, Emin; Akyol, Fadıl

doi:10.1007/s00066-019-01476-z

Cited by 6 publications

(5 citation statements)

References 36 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…the bNED rates additionally in favour of the 78 Gy group. 19 Regarding our 78 Gy group, the bNED rate of 83% after 5 years is similar to the 78% described by Ozyigit et al 28 However, the mean ADT duration was 21 months in the 78 Gy group, which is lower than the suggested 24 to 36 months of ADT 2 after Bolla et al 20 showed inferior survival after only 6 months of ADT compared to 36 months. Evidence indicates that 18 months leads to no worse outcomes than 36 months 18 , possibly reducing the recommended duration of ADT in the future.…”

Section: Discussionsupporting

confidence: 84%

“… 19 Regarding our 78 Gy group, the bNED rate of 83% after 5 years is similar to the 78% described by Ozyigit et al . 28 However, the mean ADT duration was 21 months in the 78 Gy group, which is lower than the suggested 24 to 36 months of ADT 2 after Bolla et al . 20 showed inferior survival after only 6 months of ADT compared to 36 months.…”

Section: Discussionmentioning

confidence: 56%

See 1 more Smart Citation

Advancements in the radiooncological treatment of high-risk prostate cancer: a quarter century of achievements

Moll

Herrmann

Zaharie

et al. 2022

Radiology and Oncology

View full text Add to dashboard Cite

Background The aim of the study was to evaluate the development of treatment of primary high-risk prostate cancer in regards to biochemical no evidence of disease (bNED), acute and late gastrointestinal (GI) and genitourinary (GU) side effects. Patients and methods Primary high-risk prostate cancer patients treated between 1994 and 2016 were included. Applied doses ranged from 60 to 80 Gy, with a dose of 1.8 or 2 Gy per fraction. Techniques were either 3D conformal or intensity modulated radiotherapy and volumetric intensity modulated arc therapy. Results 142 patients were treated with doses up to 70 Gy (median dose 66 Gy; 66 Gy group), 282 with doses between 70 and 76 Gy (median dose 74 Gy; 74 Gy group), and 141 with doses >76 Gy (median dose 78 Gy; 78 Gy group). The median follow-up was 48 months. The bNED rates were 50% after 5 years and 44% after 9 years in the 66 Gy group; 65% and 54%, respectively, in the 74 Gy group; and 83% and 66%, respectively, in the 78 Gy group (p = 0.03 vs. 74 Gy and p < 0.0001 vs. 66 Gy). We found a higher rate of acute GI side effects in the 78 Gy group compared to the other groups, but not in maximum acute GU side effects and late maximum GI and GU effects. Conclusions High-risk prostate cancer patients treated with doses of 78 Gy had significantly better bNED rates. Compared to the historical 66 Gy group, 50% more patients achieved bNED after a follow-up of 9 years.

show abstract

Section: Discussionsupporting

confidence: 84%

Section: Discussionmentioning

confidence: 56%

Advancements in the radiooncological treatment of high-risk prostate cancer: a quarter century of achievements

Moll

Herrmann

Zaharie

et al. 2022

Radiology and Oncology

View full text Add to dashboard Cite

show abstract

“…However, higher doses have also been shown to be associated with increased rectal toxicity [3]. Overall survival advantages have been shown in subanalyses of randomized studies [4] or non-randomized studies [5].…”

Section: Introductionmentioning

confidence: 99%

Quality of life more than 10 years after radiotherapy for localized prostate cancer—impact of time after treatment and prescription dose

et al. 2020

View full text Add to dashboard Cite

Purpose Analysis of quality of life changes after radiotherapy with focus on the impact of time after treatment and prescription dose. Methods Consecutive patients were treated with doses from 70.2/1.8 Gy (n = 206) to 72/1.8–2.0 Gy (n = 176) in a single centre and surveyed using the Expanded Prostate Cancer Index Composite questionnaire. Results Urinary and bowel bother scores decreased 1 / 3 / 6 points and 7 / 7 / 9 points on average 1 / 5 / 10 years after RT in comparison to baseline scores. The rate of urinary (need of pads in 8% vs. 15% before vs. 10 years after RT; p = 0.01) and bowel (uncontrolled leakage of stool in 5% vs. 12% before vs. 10 years after RT; p < 0.01) incontinence, as well as rectal bleeding (4% vs. 8% before vs. 10 years after RT; p = 0.05) increased. Sexual function scores decreased (erections sufficient for intercourse in 36% vs. 12% before vs. 10 years after RT; p < 0.01). A higher dose had a statistically significant impact on urinary bother and stool incontinence, but also tended to decrease urinary continence. Age and comorbidities did not have an influence on score changes, but on baseline urinary function/bother and baseline sexual function. Conclusion Apart from an increasing rate of erectile dysfunction, urinary and bowel incontinence rates increased with increasing follow-up period. A higher dose was found to be associated with increased urinary problems and larger stool incontinence rates. Age and comorbidities were found to be relevant for baseline scores, but not for score changes.

show abstract

“…A total of eight studies were selected for inclusion in the meta-analysis, all of which were retrospective series classified as Level 4 evidence [14] , [20] , [21] , [22] , [23] , [24] , [25] , [26] . Four reported data from a single institution, while the remaining four were multi-institutional.…”

Section: Resultsmentioning

confidence: 99%

Does brachytherapy boost improve survival outcomes in Gleason Grade Group 5 patients treated with external beam radiotherapy and androgen deprivation therapy? A systematic review and meta-analysis

Tang¹,

Gulstene²,

McArthur³

et al. 2023

Clinical and Translational Radiation Oncology

View full text Add to dashboard Cite

Treatment outcomes of prostate cancer patients with Gleason score 8–10 treated with definitive radiotherapy

Cited by 6 publications

References 36 publications

Advancements in the radiooncological treatment of high-risk prostate cancer: a quarter century of achievements

Advancements in the radiooncological treatment of high-risk prostate cancer: a quarter century of achievements

Quality of life more than 10 years after radiotherapy for localized prostate cancer—impact of time after treatment and prescription dose

Does brachytherapy boost improve survival outcomes in Gleason Grade Group 5 patients treated with external beam radiotherapy and androgen deprivation therapy? A systematic review and meta-analysis

Contact Info

Product

Resources

About